OneDigital Investment Advisors LLC Has $2.72 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

OneDigital Investment Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,253 shares of the biopharmaceutical company's stock after selling 3,220 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Gilead Sciences were worth $2,718,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at $25,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at $29,000. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares in the last quarter. Investment Research & Advisory Group Inc. grew its holdings in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares in the last quarter. Finally, Lee Danner & Bass Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter valued at $41,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares of the company's stock, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider directly owned 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,500 shares of company stock valued at $6,340,745. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Down 0.2%

Shares of GILD traded down $0.24 during trading hours on Friday, hitting $111.28. 4,039,811 shares of the company were exchanged, compared to its average volume of 7,706,267. The company has a market cap of $138.42 billion, a PE ratio of 23.43, a PEG ratio of 0.72 and a beta of 0.29. The firm's 50 day moving average is $107.02 and its 200-day moving average is $104.02. Gilead Sciences, Inc. has a 52 week low of $66.34 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.32) EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Morgan Stanley boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.